# Paracetamol in Patent Ductus Arteriosus

Study · id `cardio:ct-nct02422966` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02422966](<https://clinicaltrials.gov/study/NCT02422966>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02422966

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02422966. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2019-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02422966, source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)
- Started: 2015-12 (actual) (ClinicalTrials.gov record NCT02422966, source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)
- Primary completion: 2019-01 (actual) (ClinicalTrials.gov record NCT02422966, source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)
- Completion: 2019-04 (actual) (ClinicalTrials.gov record NCT02422966, source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02422966, source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02422966-2019-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Paracetamol in Patent Ductus Arteriosus
- Condition: Ductus Arteriosus, Patent
- Intervention (Drug): Paracetamol
- Intervention (Drug): Ibuprofen
- Lead sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial (`cardio:pubmed-32888085`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 405b83ececcbfe5011b8469275fb1ef46cb360752deebfa30eb26c88aff95a64
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
